Full year 2025 target operating expense of approximately $300 million
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- Options Volatility and Implied Earnings Moves Today, March 03, 2025
- TGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MaxCyte enters strategic platform license with TG Therapeutics
- TG Therapeutics Reports Strong Revenue and Future Goals
- TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M